Resultados da busca - Laird, A. Douglas
- Mostrando 1 - 8 resultados de 8
-
1
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study por Tolaney, Sara M., Nechushtan, Hovav, Ron, Ilan-Gil, Schöffski, Patrick, Awada, Ahmad, Yasenchak, Chris A., Laird, A. Douglas, O’Keeffe, Bridget, Shapiro, Geoffrey I., Winer, Eric P.
Publicado em 2016Texto -
2
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma por Wen, Patrick Y., Omuro, Antonio, Ahluwalia, Manmeet S., Fathallah-Shaykh, Hassan M., Mohile, Nimish, Lager, Joanne J., Laird, A. Douglas, Tang, Jiali, Jiang, Jason, Egile, Coumaran, Cloughesy, Timothy F.
Publicado em 2015Texto -
3
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL por Iacobucci, Ilaria, Fukano, Reiji, D. Friske, Jake, Qu, Chunxu, Janke, Laura J., Zhao, Yaqi, Baviskar, Pradyuamna, A. Backhaus, Emily, Chockley, Peter, Seth, Aman, Laird, A. Douglas, Advani, Anjali S., Mullighan, Charles G.
Publicado em 2022Texto -
4
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study por DeAngelo, Daniel J., Stock, Wendy, Stein, Anthony S., Shustov, Andrei, Liedtke, Michaela, Schiffer, Charles A., Vandendries, Erik, Liau, Katherine, Ananthakrishnan, Revathi, Boni, Joseph, Laird, A. Douglas, Fostvedt, Luke, Kantarjian, Hagop M., Advani, Anjali S.
Publicado em 2017Texto -
5
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study por Hawkes, Eliza A., Phillips, Tycel, Budde, Lihua Elizabeth, Santoro, Armando, Saba, Nakhle S., Roncolato, Fernando, Gregory, Gareth P., Verhoef, Gregor, Offner, Fritz, Quero, Cristina, Radford, John, Giannopoulos, Krzysztof, Stevens, Don, Thall, Aron, Huang, Bo, Laird, A. Douglas, Sandner, Robin, Ansell, Stephen M.
Publicado em 2021Texto -
6
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome por Cortes, Jorge E., Heidel, Florian H., Hellmann, Andrzej, Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Pollyea, Daniel A., DesJardins, Pierre, Ottmann, Oliver, Ma, Weidong Wendy, Shaik, M. Naveed, Laird, A. Douglas, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, Heuser, Michael
Publicado em 2018Texto -
7
Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study por Smith, Matthew R., Sweeney, Christopher J., Corn, Paul G., Rathkopf, Dana E., Smith, David C., Hussain, Maha, George, Daniel J., Higano, Celestia S., Harzstark, Andrea L., Sartor, A. Oliver, Vogelzang, Nicholas J., Gordon, Michael S., de Bono, Johann S., Haas, Naomi B., Logothetis, Christopher J., Elfiky, Aymen, Scheffold, Christian, Laird, A. Douglas, Schimmoller, Frauke, Basch, Ethan M., Scher, Howard I.
Publicado em 2014Texto -
8
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia por Kimura, Shunsuke, Montefiori, Lindsey, Iacobucci, Ilaria, Zhao, Yaqi, Gao, Qingsong, Paietta, Elisabeth M., Haferlach, Claudia, Laird, A. Douglas, Mead, Paul E., Gu, Zhaohui, Stock, Wendy, Litzow, Mark, Rowe, Jacob M., Luger, Selina M., Hunger, Stephen P., Ryland, Georgina L., Schmidt, Breon, Ekert, Paul G., Oshlack, Alicia, Grimmond, Sean M., Rehn, Jacqueline, Breen, James, Yeung, David, White, Deborah L., Aldoss, Ibrahim, Jabbour, Elias J., Pui, Ching-Hon, Meggendorfer, Manja, Walter, Wencke, Kern, Wolfgang, Haferlach, Torsten, Brady, Samuel, Zhang, Jinghui, Roberts, Kathryn G., Blombery, Piers, Mullighan, Charles G.
Publicado em 2022Texto